Biostar Pharmaceuticals Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 8.00 M
as on 06-07-2024
- Paid Up Capital ₹ 7.50 M
as on 06-07-2024
- Company Age 38 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 28.00 M
as on 06-07-2024
- Revenue 388.15%
(FY 2021)
- Profit 2371.54%
(FY 2021)
- Ebitda -21.92%
(FY 2021)
- Net Worth 166.04%
(FY 2021)
- Total Assets 0.75%
(FY 2021)
About Biostar Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 8.00 M and a paid-up capital of Rs 7.50 M.
The company currently has active open charges totaling ₹2.80 Cr.
Ashok Bora, Abhay Bora, and Shakuntala Bora serve as directors at the Company.
- CIN/LLPIN
U24232PN1986PTC039850
- Company No.
039850
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 May 1986
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Biostar Pharmaceuticals Private Limited offer?
Biostar Pharmaceuticals Private Limited offers a wide range of products and services, including Infusion Syringes & Supplies, Medical Tubes.
Who are the key members and board of directors at Biostar Pharmaceuticals?
Board Members(3)
Financial Performance and Corporate Structure Insights of Biostar Pharmaceuticals.
Biostar Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 388.15% increase. The company also saw a substantial improvement in profitability, with a 2371.54% increase in profit. The company's net worth Soared by an impressive increase of 166.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biostar Pharmaceuticals?
In 2021, Biostar Pharmaceuticals had a promoter holding of 94.98% and a public holding of 5.02%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
10 years 3 months Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Banque Nationale De Paris Creation Date: 14 Mar 2000 | ₹1.65 Cr | Open |
Janata Sahakari Bank Ltd. Creation Date: 06 Nov 1995 | ₹1.15 Cr | Open |
How Many Employees Work at Biostar Pharmaceuticals?
Biostar Pharmaceuticals has a workforce of 3 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biostar Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biostar Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
